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Abstract
The development of antibodies with binding capacity towards soluble oligomeric forms of PrPSc recognised in the
aggregation process in early stage of the disease would be of paramount importance in diagnosing prion diseases before
extensive neuropathology has ensued. As blood transfusion appears to be efficient in the transmission of the infectious prion
agent, there is an urgent need to develop reagents that would specifically recognize oligomeric forms of the abnormally
folded prion protein, PrPSc. To that end, we show that anti-PrP monoclonal antibodies (called PRIOC mAbs) derived from
mice immunised with native PrP-coated microbeads are able to immunodetect oligomers/multimers of PrPSc. Oligomer-
specific immunoreactivity displayed by these PRIOC mAbs was demonstrated as large aggregates of immunoreactive deposits
in prion-permissive neuroblastoma cell lines but not in equivalent non-infected or prn-p0/0 cell lines. In contrast, an anti-
monomer PrP antibody displayed diffuse immunoreactivity restricted to the cell membrane. Furthermore, our PRIOCmAbs did
not display any binding with monomeric recombinant and cellular prion proteins but strongly detected PrPSc oligomers as
shown by a newly developed sensitive and specific ELISA. Finally, PrioC antibodies were also able to bind soluble oligomers
formed of Ab and a-synuclein. These findings demonstrate the potential use of anti-prion antibodies that bind PrPSc
oligomers, recognised in early stage of the disease, for the diagnosis of prion diseases in blood and other body fluids.
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Introduction
Protein aggregates are believed to be the cause of various
neurodegenerative disorders, including prion diseases [1]. Soluble
oligomeric forms that are recognised in the aggregation process
can lead to synaptic dysfunction, whereas large, insoluble deposits
are believed to function as reservoirs of the bioactive oligomers [1].
Furthermore, in Alzheimer’s disease (AD) and Parkinson’s disease
(PD), oligomeric forms of amyloid b and -synuclein respectively
are believed to form in early phases of diseases and are present in
blood and other tissues [2,3].
The apparent lack of useful specific immune responses is
considered a hallmark of prion diseases. Several studies have failed
to demonstrate detectable immune responses during the natural
course of prion disease reflecting in part the widespread expression
of the normal cellular prion protein and the identical primary
structure of PrPC and PrPSc leading to B and/or T cell tolerance
of disease-associated isoform [4,5].
Anti-PrP monoclonal antibodies have successfully been raised
using various protocols through immunizing Prn-p0/0 mice [6–14].
However, only few antibodies have so far displayed the ability to
recognize the native non-denatured forms of PrP probably due to
the fact that these native proteins lack the capacity to stimulate an
immune response in experimental animal models [4,7,9,15–18].
In previous work, we showed that immunization of mice
with native PrP-coated microbeads led to a mono-specific IgM
polyclonal immune response with binding restricted to a motif
between PrP amino acids 101–120, [19]. After we demonstrated
immunodominance of this specific motif of native PrPSc, Jones
and colleagues successfully used PrP peptides derived from this
region to produce PrPSc-specific antibodies [11].
In this study, and following immunization of Prn-p0/0 mice with
native PrP-coated microbeads, we produced monoclonal antibodies
(called PRIOC mAbs) that immunodetect oligomeric forms of
native PrPSc as well as other amyloidogenic proteins and peptides.
These oligomer-specific mAbs were characterised by ELISA,
Western blotting, immunoprecipitation and immunofluorescence
imaging and did not display any binding to monomeric recombi-
nant PrP and cellular prion protein in brain tissue of mice as well
as monomers and fibrils of other amyloidogenic proteins. All
PRIOC mAbs were IgM isotype, consistent with all PrPSc-specific
antibodies raised to date by other researchers [8,11,20,21].
PRIOC mAbs could potentially be used for the Immunodetec-
tion of soluble oligomeric forms of prions in blood of individuals
affected with prion disease and other misfolding diseases.
Results
1. PRIOC mAbs recognise mouse synthetic prion peptides
but not monomeric rPrP
Overlapping 20-mer peptides spanning the mouse PrP sequence
90–230 were produced. Depending on the way the immunogen
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was prepared, the PRIOC mAbs bound different PrP regions.
PRIOC2 and PRIOC1 mAbs raised against PrPSc-Dynabeads
without prior treatment recognised an amino-terminal epitope
between residues 90–109 (Fig. 1). This was identical to the
polyclonal anti-sera pep-scan analysis described previously [19].
PRIOC4 mAb appeared to bind to a more C-terminal region of
the protein sequence between 170–189. Of note, this region
includes the YYR motif used by Paramthiosis and colleagues to
raise their PrPSc-specific antibody [21].
Finally, PRIOC3 mAb raised against PrPSc that was first heat-
treated before being adsorbed to Dynabeads, weakly bound the
170–189 region of the prion protein similar to that seen with
PRIOC4. The results seen with both PRIOC3 and PRIOC4 mAbs
are similar to binding seen with the polyclonal antibody response to
PrPSc-Dynabeads where the prion-infected brain homogenate was
heat treated prior to adsorption to the Dynabeads [19].
PRIOC mAbs were screened for reactivity to full-length and
truncated mouse or recombinant prion proteins. None of the
mAbs reacted to both and conformations of rPrP with ELISA
(data not shown). Furthermore, the isotype of PRIOC mAbs was
checked by isotype ELISA and as expected from the polyclonal
responses [19], the monoclonal antibody isotype was exclusively
IgM (data not shown).
2. PRIOC mAbs bind native PrPC/Sc
Surface PrPC/Sc expression on prion-permissive cell lines,
including ScN2a, was shown to be high with anti-PrP antibodies
raised against recombinant prion proteins [22]. PRIOC mAbs
were also probed in the same way in order to demonstrate whether
binding to surface native PrPC/Sc occurred (Fig. 2). In general
PRIOC mAbs bound weakly to the surface of ScN2a cells than the
anti-PrP positive control (Fig. 2B), possibly reflecting a lower
affinity for PrPC/Sc and/or scarcity of oligomeric forms of PrPSc
found in these cells.
3. PRIOC mAbs bind native murine and human but not
native ovine and bovine PrP
Normal and scrapie brain homogenate was proteinase K treated
and the PRIOC mAbs used to immunoprecipitate PrPC and PrPSc
frommurine, human, ovine, and bovine brain homogenates (Table 1).
Treatment with proteinase K cleaves approximately 67 amino acids
from N-terminus of PrPSc and completely digests PrPC. An anti-PrP
antibody (biotin-conjugate), which detects all glycoforms and
fragments of PrPC, was used to analyse the immunoprecipitate by
western blots after denaturation by boiling in sample buffer for 5 min.
After PK treatment, PrPC was completely digested, whereas the 33–
35 kDa form of PrPSc was shortened to 27–30 kDa, as a result of
degradation of the amino-terminal segment of residues 23–90
analogous to hamster PrPSc [23]. Immunoprecipitation of both
control and scrapie-infected brain homogenates with PRIOC mAbs
including, PRIOC1, 2, 3 and 4 was performed (Table 1 and Fig. 3 &
Fig. 4). The homogenates were proteinase K treated (or not) before
incubation with PRIOCmAbs. PRIOC1 mAb bound RML-infected
brain homogenates after PK digestion but failed to recognize both
mouse and human control brain homogenates (Fig. 3A & Fig. 4). It
was also interesting to note that PRIOC1 reacted strongly with type 4
CJD brain homogenates only after PK treatment (data not shown). In
contrast, PRIOC2, 3 and 4 bound very strongly to RML-infected
brain homogenates and human type 4 CJD whether PK-digested or
not (Table 1 and Fig. 3B, C & D) but failed to recognise control
homogenate (Fig. 3B, C & D). Of note, all PrioC mAbs failed to
display any detectable binding with sporadic CJD (sCJD) with and
with no denaturation of the tissue homogenate as tested by Western
blotting and immunohistochemistry (data not shown).
Figure 1. Pep-scan of PRIOC mAbs generated with bead-bound PrPSc. PRIOC1, 2, 3 and 4 mAbs produced in Prn-p0/0 mice immunised with
PrP-coated microbeads were investigated using mapping ELISA coated with 20-mer peptides spanning the 90–219 region of the mouse PrP protein.
Goat anti-mouse IgM HRP-conjugate was used as secondary detection antibody. An IgG anti-PrP antibody (Sigma) that binds to a region between
143–153 was used as positive control and an antibody isotype-matched control was used as negative control. Anti-PrP responses were measured in
peptide ELISA. Values represent the mean 6S.D. of three independent experiments.
doi:10.1371/journal.pone.0019998.g001
Immunodetection of PrPSc Oligomers
PLoS ONE | www.plosone.org 2 May 2011 | Volume 6 | Issue 5 | e19998
Finally all PRIOC mAbs poorly bound any form of both ovine
and bovine brain homogenates (Fig. 4), indicating that the
immunogen had a direct influence on species-specificity of these
antibodies, but other factors could also be involved.
4. PRIOC mAbs immunodetect PrPSc oligomers with
immunofluorescence staining
The distribution of oligomer-specific immunoreactivity was
examined in N2a, ScN2a and a prn-p0/0 glial [24] cell line following
binding with PRIOC mAbs (Fig. 5 & Fig. 6). Oligomer-specific
immunoreactivity is demonstrated as large aggregates of immuno-
reactive deposits in ScN2a with (Fig. 5 A, B, C & D) and with no cell
permeabilisation (Fig. 5 E & F). In Sharp contrast, anti-PrP antibody
positive control displayed the traditional staining pattern focused on
the cell membrane decorating it with a ring and appears to be
surrounded peripherally by large deposits (Fig. 5). PrioC mAbs
failed to bind to both N2a and the prn-p0/0 glial cell, indicating their
specific recognition of oligomers associated with prion replication in
ScN2a cell lines (Fig. 6). These results suggest that PRIOC mAbs
are able to bind a different species of PrPSc; the oligomeric forms, in
contrast with the monomers bound by the control antibody.
5. PRIOC mAbs immunodetect native PrPSc in ELISA
In order to quantify levels of PrPSc oligomers in RML-infected
brain homogenates, and to prove the specificity of the PRIOC
mAbs in detecting oligomeric forms, we developed a specific and
Figure 2. FACS analysis using PRIOC mAbs on ScN2a cells. PRIOC1, 2, 3 and 4 mAbs were used to probe PrP on ScN2a cells. Secondary anti-
IgM FITC conjugate was used. Positive and isotype matched FITC conjugate were also used. A. cells incubated with anti-IgM FITC conjugate negative
control B. cells strongly reacted with positive control anti-PrP antibody FITC conjugate C. cells reacted poorly with PRIOC1 FITC conjugate D. cells
reacted mildly with PRIOC2 FITC conjugate. E. cells reacted mildly with PRIOC3 FITC conjugate F. cells reacted mildly with PRIOC4 FITC conjugate.
Representative of three experiments.
doi:10.1371/journal.pone.0019998.g002
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sensitive novel Sandwich ELISA that relies on a non-denaturing
protocol designed to immunodetect only the oligomeric species of
PrPSc. The assay is based on a Sandwich system that includes an
immunocapture PRIOC antibody, able to detect the oligomers,
followed by immunodetection with the same PRIOC mAb in a
biotinylated form (Fig. 7A). Since PrP monomers are not bound by
PRIOC antibody immunocapture, no signal was detected, in
contrast, PRIOC antibody binding to oligomers displayed strong
signal following immunodetection and substrate stimulation
(Fig. 7).
Immunodetection with an anti-PrP antibody able to detect
monomeric forms of PrP with subsequent immunodetection with
PRIOC antibodies led to a strong positive signal. Of note all
PRIOC antibodies detected PrPSc oligomers following capture
with anti-monomer antibody (Fig. 7B). In sharp contrast, capture
with PRIOC antibodies followed with detection using the anti-
monomer antibody failed to give any signal; which strongly
indicates that PRIOC mAbs bind to a conformational epitope
formed as a consequence of the aggregation process.
6. PRIOC mAbs immunodetect rPrP oligomers in ELISA
We also tested the ability of PrioC mAbs to detect synthetic
oligomers produced from recombinant PrP (rPrP) (Fig. 8). We
show that only the oligomeric species derived from monomeric
rPrP were immunodetected by PrioC mAbs which failed to bind to
both the monomers and the fibrils (Fig. 8A and data not shown).
The intensity of Thioflavin T stain of the fibrils derived from
monomeric rPrP was inversely proportional to soluble oligomer
levels detected by PRIOC mAbs (Fig. 8B), suggesting that the
conformational epitope recognized by these mAbs is transitional
and its structural availability is phase-specific during the
oligomerisation process (8C) [25,26].
7. PRIOC mAbs recognise oligomers derived from
monomeric Ab peptide and a-synuclein
We investigated the ability of PrioC mAbs to bind soluble
oligomers derived from monomeric Ab peptide and a-synuclein by
Sandwich ELISA (Fig. 9). All PRIOC mAbs tested were unable to
recognize the monomeric isoforms and fibrils but bound strongly to
the soluble oligomers derived from Ab peptide and a-synuclein.
Kayed and colleagues have previously shown that oligomer-specific
serum raised against Ab peptide oligomers were able to detect other
amyloidogenic proteins and peptides, including a-synuclein, islet
amyloid polypeptide (IAPP), polyglutamine, lysozyme, human
insulin, and prion peptide 106–126, but failed to recognize either
the soluble low-MW species or the fibrils [26]. In agreement, our
results indicate that, independently of their primary sequences, a
conformational motif common to these amyloidogenic proteins is
immunodetected by the PRIOC mAbs.
Discussion
Previous studies suggest that the toxicity of many amyloidogenic
proteins that cause neurodegeneration and neuronal death derive
from the soluble oligomeric forms rather than the mature amyloid
fibrils believed to act as reservoirs [27–30].
The development of reagents that specifically detect these
soluble toxic forms in prion disease would be a useful tool to
unravel the aggregation process and would help in the diagnosis of
the disease by demonstrating the presence of the oligomers in early
stages of the disease. To that end, monoclonal antibodies, called
PRIOC mAbs were generated in Prnp0/0 mice immunised with
RML-infected mouse brain homogenate, corresponding to the
protease resistant fragment PrP27–30. These brain homogenates
have undergone differential treatment prior to adsorption to the
Dynabeads, used as immunogen.
A total of four PRIOC mAbs produced in PrP0/0 mice
immunised with PrPSc-Dynabeads, none of which bound to a-
or b-rPrP isoforms.
Unexpectedly and except for PRIOC3 that showed weaker
binding, All PRIOC mAbs seem to strongly bind linear epitopes as
shown by peptide ELISA. Failure of the PrioC mAbs to bind to
rPrP while retaining their capability to recognize linear peptides
could be explained by the possibility that that PRIOC mAbs are
specifically binding to a motif not exposed (or buried) in the
recombinant prion protein. Further, binding to a linear peptide
does not necessarily mean that the PRIOC mAbs antibodies
strictly recognise a linear motif on the prion protein, but more
likely bind a conformational epitope as indicated by the
competition ELISA with sera from mice immunised with the
same immunogen [19]. Furthermore, PRIOC mAbs did not detect
native prion proteins by SDS-PAGE electrophoresis with no
sample boiling (data not shown), strongly indicating that these
antibodies recognise a conformational epitope. This is in
agreement with the work of Korth and colleagues [8] where
mAb 15B3 recognised three polypetides on the prion protein that
were not linear or sequential but were revealed to be contiguous
Table 1. Immunoprecipitation profile of PRIOC mAbs with various brain homogenates.
WT WTPK RML RMLPK H HPK T4 T4PK
PRIOC1 + 2 + +++ + 2 + +++
PRIOC2 2 2 +++ +++ 2 2 ++ ++
PRIOC3 2 2 +++ +++ 2 2 ++ ++
PRIOC4 2 2 +++ +++ 2 2 ++ ++
SC SCPK ScC ScCPK BOV BOVPK BSE BSEPK
PRIOC1 2 2 + + + 2 + +
PRIOC2 + 2 + + 2 2 + +
PRIOC3 2 2 2 2 2 2 2 2
PRIOC4 + 2 + + + 2 + +
WT (mouse control), RML (scrapie-infected mouse), H (human control), T4 (vCJD), SC (sheep control), ScC (scrapie-infected sheep), BOV (bovine control), and BSE were all
immunoprecipitated with PRIOC mAbs with and without proteinase K (PK) prior to immunocapture.
doi:10.1371/journal.pone.0019998.t001
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with NMR studies. Williamson and colleagues [31] have also
shown that their antibodies mapped ‘‘discontinuous epitopes’’ but
bound denatured prion protein.
PRIOC mAbs did not bind native PrPC in mouse control brain
homogenates. These results were similar to those shown for binding
to control human brain precipitates, where no binding was
demonstrated by the PRIOC mAbs. Although all PRIOC mAbs
were raised with mouse PrP, cross-reactivity with human PrP, as
shown with immunoprecipitation was not surprising as PrP is
conserved across species and human and mouse PrP share 98.9%
homology [32]. This is also seen with antibodies we raised
previously which recognise PrP of all species tested [33]. Similar
findings were also observed by other researchers [4,31,34].
Heat treatment of RML-infected brain homogenate, prior to
adsorption to the Dynabeads, seems to have influenced specific
PrP isoform recognition. PRIOC mAbs did not recognise all forms
of control mouse and human brain homogeates but also ovine and
bovine brain homogenates following immunoprecipitation.
Most of the PRIOC mAbs had similar pattern of binding
detecting PrPSc in mouse and human but showed stronger
immunodetection of mouse RML as opposed to type 4 CJD.
Molecular classification of human prion diseases has led to the
recognition of distinct isolates, or strains [35,36] with the different
fragment sizes seen on Western blots, following proteinase K
treatment, suggesting that there are several different human PrPSc
conformations. This has also been observed in mink and hamsters
[37,38]. Prion strains can be classified by the ratio of the three PrP
bands seen after protease cleavage, corresponding to amino-
terminal truncated products generated from di-, mono, or non-
glycosylated PrPSc. All PRIOC mAbs have immunodetected
RML strain and type 4 CJD with immunoprecipitation and
PRIOC2, PRIOC3 and PRIOC4 displayed stronger binding for
PrPSc in mouse and human. Treatment of the immunogen prior
to immunisation influenced the pattern of binding with various
PrP species.
The untreated homogenate that stimulated both PRIOC1 and
PRIOC2 demonstrated similar binding pattern as both PRIOC1
and PRIOC2 immunodetected RML-infected brain homogenate
and type 4 CJD after PK-digestion. Of note, PRIOC1 did not show
binding with either if not subjected to PK digestion. These results
demonstrate that differential treatment/binding of the immunogen
Figure 3. Immunoprecipitation of PRIOC mAbs (5 mg/ml) with
murine PrP from brain homogenates (1% w/v). A. PRIOC1
immunocapture precipitates from mouse PrPSc but not PrPC with and
with no PK treatment B. PRIOC2 immunocapture precipitates from
mouse PrPSc but not PrPC with and with no PK treatment C. PRIOC3
immunocapture precipitates from mouse PrPSc but not PrPC with and
with no PK treatment D. PRIOC4 immunocapture precipitates from
mouse PrPSc but not PrPC with and with no PK treatment E. Anti-PrP
antibody positive control used to immunocapture precipitates from
Prn-p0/0 and PrPSc with and with no PK treatment. Purified PRIOC
antibody was used for immunodetection. Representative of three
experiments.
doi:10.1371/journal.pone.0019998.g003
Figure 4. Immunoprecipitation of PRIOC1 mAb (5 mg/ml) with
human, bovine and ovine PrP from brain homogenates (1%
w/v). PRIOC1 strongly immunocaptures precipitates from human type
4 CJD homogenate but not PrPC with PK treatment. In contrast,
PRIOC1poorly immunocaptures precipitates from bovine and ovine
PrPC and PrPSc with PK treatment. Representative of three experiments.
doi:10.1371/journal.pone.0019998.g004
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has not led to dissimilar binding patterns but the observation of
different outcomes with some antibodies suggests that the host plays
an important role in defining the outcome of the antibody response.
Unsurprisingly, all PRIOC mAbs were of the IgM isotype,
similar to the polyclonal responses [19]. All PrPSc-specific
antibodies raised to date have been IgM [8,20,21], an indication
that the immune system uses a pathway that is specific for
generating PrPSc-specific antibodies involving perhaps specific B
cells that recognise fragments of the prion protein associated with
disease only.
PRIOC mAbs were used to assess the distribution of PrPSc
immunoreactivity in ScN2a cells by immunofluorescence. Sur-
prisingly, staining with PRIOC mAbs was demonstrated as large
aggregates of immunoreactive deposits while staining with an anti-
PrP antibody led to a more diffuse pattern forming a ring around
the cell membrane. In contrast, these mAbs failed to show any
Figure 5. Immunofluorescence staining of PrPSc oligomers/multimers with PRIOC mAbs. PRIOC extensively stained large aggregates in
ScN2a cells. (A). Staining with PRIOC1 did not display PrPSc oligomer-specific stain. (B). PRIOC2, (C) PRIOC3 and (D) PRIOC4 displayed distinct and
unusual staining (yellow arrows) in ScN2a cells (green) as opposed to an anti-monomer antibody that displayed the typical diffuse ring-shaped stain
of the cell membrane (red). Following permeabilization, ScN2a cells displayed similar stain for aggregates using (E). PRIOC2 and (F). PRIOC2.
Florescence microscopy was performed and images from each source [FITC (450–490 nm), Texas red (510–560 nm) and DAPI (330–380 nm)] were
collected. Scale bar = 25 mm.
doi:10.1371/journal.pone.0019998.g005
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staining with N2a as well prn-p0/0 glial cells. Kayed and colleagues
have previously shown that anti-oligomer antibodies revealed that
soluble oligomers display a common conformation-dependent
structure found only in soluble oligomers independent of their
sequences [26]. In agreement with our study, their anti-oligomer
antibody displayed a similar binding pattern showing clusters of
immunoreactive deposits. Moreover, the seemingly weak binding
of PRIOC mAbs with flow cytometry studies can be explained by
the scarcity of the aggregates, which indicates that our antibodies
recognize PrPSc oligomers. To further prove that PRIOC mAbs
immunodetect a conformation-dependent structure formed by the
aggregation-oligomerization process, we developed a specific and
sensitive Sandwich ELISA that enabled us to detect PrPSc
oligomers/multimers, rPrP, Ab and a-synuclein oligomers but
not their monomeric and fibril counterparts.
Immunocapture of PrP oligomers with PRIOC antibodies with
subsequent immunodetection with anti-oligomer PRIOC mAbs
led to strong signals in contrast with immunodetection with anti-
PrP monomer antibody that displayed no signal. The Sandwich
assay format used in this study has previously been applied for the
detection of a-synuclein oligomers using conformation-dependent
anti-a-synuclein oligomers antibody [2,3]. In agreement, our
results displayed similar binding ability of PrPSc oligomers using
PRIOC mAbs. Surprisingly, PRIOC mAbs were able to detect
soluble oligomers derived from rPrP and other amyloidogenic
peptide/protein such Ab peptide and a-synuclein but failed to
display binding to the monomers and fibril isoforms. Further,
levels of rPrP oligomers as assessed by PRIOC binding were
inversely proportional to fibril formation measured by ThT
fluorescence reflecting the dynamic aggregation process of the
amyloidogenic proteins.
Taken together our results strongly indicate that these novel
PRIOC mAbs raised in Prn-p0/0 mice using native PrP-coated
microbeads bind specifically to amyloidogenic oligomers/multi-
mers but not the monomers and the fibrils.
PRIOC mAbs antibodies could potentially be used for the
development of a blood-based diagnostic test screen that would
detect PrPSc and other oligomers in preclinical prion disease and
work is currently underway to achieve this aim.
Materials and Methods
1. Ethics Statement
All procedures involving animals were carried out under a
project and personal licence authority issued in accordance with
The Animals (Scientific Procedures) Act 1986 and approval by
the Royal veterinary College Ethics Committee (approval ID:
MT:Towards Immunotherapy for prion diseases, PIL 70/14970).
Figure 6. Immunofluorescence staining of N2a and prn-p0/0 cell lines with PRIOC mAbs. PRIOC mAbs failed to stain prion aggregates in
N2a and prn-p0/0 glial cells. (A). Staining with PRIOC4 did not display PrPSc oligomer-specific stain in prn-p0/0 glial cells with no permeabilization. (B).
Staining with PRIOC4 did not display PrPSc oligomer-specific stain in N2a cells with no permeabilization. (C). Staining with PRIOC4 did not display
PrPSc oligomer-specific stain in prn-p0/0 glial cells following permeabilization. (D). Staining with PRIOC4 did not display PrPSc oligomer-specific stain
in N2a cells following permeabilization. Florescence microscopy was performed and images from each source [FITC (450–490 nm), Texas red (510–
560 nm) and DAPI (330–380 nm)] were collected. Scale bar = 25 mm.
doi:10.1371/journal.pone.0019998.g006
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Mice with ablation of both alleles of the single copy PrP gene [39]
(Prn-p0/0) backcrossed onto an FVB/N strain background
(Harlan-Olac UK) were used in the experiments.
2. Production of PRIOC monoclonal antibodies
FVB/N Prn-p0/0 mice were immunised subcutaneously with
Dynabead-adsorbed PrP in CFA on day 0 then in IFA on days 21,
42, and then finally boosted intraperitoneally on day 50 in PBS
instead of adjuvant. PrPSc was first digested with proteinase K
(50 mg/ml) for 30 minutes at 37uC to remove PrPC prior to
adsorption to the Dynabeads. Hybridomas were screened for
reactivity to both native PrPC and PrPSc. Positive hybridomas
were repeatedly cloned until stable (Table 2). The isotype of these
hybridomas was determined. The IgM-producing hybridomas
Figure 7. Immunodetection of PrPSc oligomers/multimers with PRIOC mAbs by Sandwich ELISA. (A). Principle of a newly developed
specific and sensitive ELISA designed for the detection of PrPSc oligomers/multimers. (B). RML-infected brain homogenates were used to assess
specific binding of PRIOC mAbs to PrPSc oligomers following proteinase K (PK) digestion. 50 ml of 5 mg/ml of PRIOC or anti-monomer antibody (AB)
was used to coat the ELISA plate in coating buffer. RML-infected brain homogenate was added to the wells followed by a biotinylated PRIOC mAb or
anti-monomer antibody (AB). The sandwich format of the assay has established the specificity of PRIOC antibody for post-PK PrPSc oligomers. Error
bars represent the mean antibody level derived from n=4 wells.
doi:10.1371/journal.pone.0019998.g007
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were unstable when using NS0 cells as fusion partner. Kim and
colleagues have shown that SP2/0 myeloma cells express very little
PrPC [40]. Using SP2/0 cells as fusion partner had overcome the
problem of spontaneous cell death; hence subsequent fusions were
performed using this particular myeloma line. Furthermore,
the IgM-producing hybridomas were shown to grow better in
Dubelco’s modified Eagle’s medium (DMEM) as compared with
RPMI.
3. Biotinylation of PRIOC mAbs
The biotinylation procedure used here was a simple method
of conjugation using EZ-link Sulpho-NHS-LC-LC biotin (Molec-
ular Weight: 443.43, Pierce). First, PRIOC mAbs were dialysed or
buffer exchanged into PBS pH 7.8 (no preservatives). Buffer
exchange was performed using Slide-A-Lyzer 10K MWCO
Dialysis cassettes (Pierce). In order to achieve efficient labelling,
all traces of free amines were removed through at least 5 buffer
washes.
Just prior to labelling, 1 mg of biotin was dissolved in 0.5 ml
H2O to achieve a 2 mg/ml solution. From the biotin solution,
37 ml volume was added to a 1 mg/ml solution of PRIOC mAb in
order to achieve a challenge molar ratio of 20:1 biotin:PRIOC.
The mixture was then incubated for 1 hour at RT on a rotator.
The reaction was stopped by the addition of 40 ml/ml of 2 M
Figure 8. Immunodetection of rPrP oligomers/multimers with
PRIOC mAbs by Sandwich ELISA. (A). Oligomers derived from
rPrP monomers were used to assess specific binding of PRIOC mAbs.
50 ml of 5 mg/ml of PRIOC was used to coat the ELISA plate in
coating buffer. rPrP-derived oligomers were added to the wells
followed by a biotinylated PRIOC mAb. (B). Fibrils derived from rPrP
monomers (used to produce the oligomers) were assayed with
thioflavin T fluorescence (Tht). (C). This panel represents a
combination of panel (A) and panel (B) and demonstrates the
dynamic of oligomer/fibril formation of monomeric rPrP as assessed
by the PRIOC mAbs and Tht. Error bars represent the mean level
derived from n = 4 wells.
doi:10.1371/journal.pone.0019998.g008
Figure 9. Immunodetection of Ab peptide and a-synuclein
oligomers/multimers with PRIOC mAbs by Sandwich ELISA.
Oligomers derived from Ab peptide and a-synuclein monomers were
used to assess specific binding of PRIOC mAbs. 50 ml of 5 mg/ml of
PRIOC was used to coat the ELISA plate in coating buffer. Ab peptide or
a-synuclein-derived oligomers were added to the wells followed by a
biotinylated PRIOC mAb. Error bars represent the mean antibody level
derived from n= 4 wells.
doi:10.1371/journal.pone.0019998.g009
Table 2. Differential treatment of PrPSc-infected material
prior to adsorption to the Dynabeads used to produce PRIOC
mAbs.
Fusion
partner Stability Immunogen
PrPSc treatment/
binding
PRIOC1
NS/0 ‘Unstable’ PrPSc-Dynabeads None
PRIOC2
SP2/0 Stable PrPSc-Dynabeads None
PRIOC3
SP2/0 Stable PrPSc-Dynabeads Heat-treated
PRIOC4
SP2/0 Stable PrPSc-Dynabeads Congo red
All PRIOC mAbs have been generated in Prn-p0/0 mice immunised with PrP-
Dynabeads following treatment with heat, Congo red or no treatment.
doi:10.1371/journal.pone.0019998.t002
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glycine. Free unbound biotin was removed through dialysis of the
biotinylated antibody against PBS.
Finally, for storage, sodium azide (NaN3) was added to the
biotinylated antibody to achieve 0.1% final concentration, as well
as trypsin inhibitor (Sigma) to achieve a 2% final concentration.
The biotinylated PRIOC mAbs were then aliquoted and stored at
220C.
4. Murine synthetic peptides
Peptides were synthesized by automated solid phase step-wise
synthesis using the Fmoc N terminal protection chemistry. Peptides
were cleaved from the solid phase and fully side-chain deprotected
using trifluoroacetic acid with water and tri-isopropylsilane as
scavengers. Cleaved peptides were precipitated and washed in ice-
cold methyl tertiary butyl ether, dried, dissolved in suitable aqueous
solvents and analysed by reverse phase HPLC and MALDI-TOF
mass spectrometry. Purified fractions were freeze-dried and then
reconstituted in either water or PBS prior to use [19].
5. Production of soluble oligomers and fibrils from
monomeric rPrP, Ab peptide and a-synuclein
Soluble oligomers and fibrils derived from their equivalent
monomeric isoforms were produced as previously described
[26,41]. Briefly, soluble oligomers were produced by adding 1 mg
protein/peptide into 400 ml (hexafluoro-2-propanol) HFIP. The
solution (100 ml) was added to 900 ml ddH2O and incubated for 10–
20 min at RT, which was then centrifuged for 15 min at 14,0006g.
The samples were then stirred at 500 rpm for 24 to 48 h at 22uC
and 10 ml aliquots were frozen at 6–12 h. The fibrils derived from
the monomeric isoforms were prepared as described previously
[26]. The Thioflavin T (ThT) fluorescence intensity of the samples
was recorded following incubation of 200 ml sample with ThT.
6. Enzyme-linked immunosorbent assay (ELISA)
6.1. Epitope mapping with synthetic prion peptides. High
binding, 96 well plates (Greiner) were coated with 50 ml/well of a
10 mg/ml peptide solution in coating buffer (35 mM NaHCO3,
15 mM Na2CO3, pH 9.6). The plates were incubated for 1 hour at
37uC then washed 3 times with PBS-0.05% tween 20, and then
blocked for 1 h at room temperature. 1 mg/ml of the primary
antibody diluted in PBS-0.05% tween 20 was added and incubated
for 1 hour at 37uC. The plates were then washed 3 times with PBS-
0.05% tween and a 1/1000 dilution of horseradish-peroxidase (HRP)
conjugated mouse anti-IgM was added for 25 min at 37uC and the
plates were again washed 4 times with PBS-0.05% tween. Finally, the
plates were developed with OPD buffer (Sigma) until optimum
development occurred, when the reaction was stopped with 3 M
sulphuric acid prior to spectrophotometric reading at 490 nm.
6.2. Direct ELISA for detection truncated recombinant
PrP. This assay was performed as described above, except that
medium binding, 96 well plates (Greiner) were used and coated
with 50 ml/well of a 10 mg/ml recombinant protein solution in
coating buffer.
6.3. Sandwich ELISA for detection of soluble oligo-
mers. Medium binding, 96 well plates (Greiner) were coated
with 50 ml/well of a 5 mg/ml PRIOC antibody solution in coating
buffer. The plates were incubated for 1 hour at 37uC then washed
3 times with PBS-0.05% tween, and then blocked for 1 h at room
temperature. Brain homogenate diluted to 0.5% in PBS-0.05%
tween 20 (w/v) with protease inhibitors (Roche Biochemicals) or
10 mg/ml rPrP, Ab peptide or a-synuclein was added and
incubated for 1 hour at 37uC. The plates were then washed 3
times with PBS-0.05% tween and a 5 mg/ml of biotinylated
PRIOC antibody was added for 1 hour at 37uC and the plates
were again washed 3 times with PBS-0.05% tween before addition
of a 1/1000 dilution of horseradish-peroxidase (HRP) conjugated
streptavidin (Sigma) for 25 min at 37uC and the plates were again
washed 4 times with PBS-0.05% tween. Finally the plates were
developed with OPD buffer until optimum development occurred
when the reaction was stopped with 3 M sulphuric acid prior to
spectrophotometric reading at 490 nm.
7. Immunoprecipitation of PrPSc from various species
Brain tissues from scrapie-infected wild type FVB/N mice were
homogenised (10% w/v in PBS) using an Ultra Turrax tissue
homogeniser (SIS), and centrifuged for 15 min at 10006g. In other
experiments, brain tissues from human, bovine and ovine were
processed in the same way. The supernatants were stored at280uC
until use. Homogenates were diluted to 0.5% in complete Lysis-M
buffer with Pefabloc SC plus protease inhibitors (Roche). The
mixture was then incubated (1:1 dilution) with PRIOC antibody for
2 h rotating continuously at 4uC. The immune complexes were
then adsorbed overnight to 16106 anti-IgM-Dynabeads (Invitro-
gen) rotating continuously at 4uC. The Dynabeads were then
washed (four times) using wash buffer. The PrP adsorbed mAb-
coated Dynabeads were resuspended in Laemmli buffer [42], and
heated to 95uC for 5 min. The beads were finally pelleted and the
supernatants used for subsequent Western blotting.
8. SDS polyacrylamide gel electrophoresis (SDS-PAGE)
SDS-PAGE pre-cast gels (Invitrogen) were used. Samples to be
electrophoresed were diluted 1:1 in 40 ml sample buffer and boiled
for 5 min in screw-cap eppendorf tubes. The samples were spun
for 5 seconds at 14.000 rpm in a microfuge before being loaded on
the gel. The gels were electrophoresed at a constant voltage of
200V for 1 h. Following electrophoresis, gels were blotted onto
Invitrolon PVDF (Invitrogen) in the POWER-PAC (BIO-RAD),
at 18V for 45 min. Following blotting, the membranes were rinsed
in PBS-tween (0.05%) before being transferred to blocking solution
for 60 min at room temperature. The membranes were again
rinsed in PBS-tween (0.05%) to remove all traces of blocking
solution. An anti-PrP mAb (Sigma) raised against the prion
peptide 143–153 in goat was added and incubated for 1 h at room
temperature. Following 4 washes of 5 min each, the membranes
were then incubated in anti-goat IgG HRP-conjugated antibody
diluted at 1 in 10,000. The membranes were washed as above and
developed using the Hybond-chemiluminescence (ECL) system
(GE Healthcare), according to the manufacturer’s instructions.
Signal development times ranged from 1 second to 30 min.
9. Cell culture
Mouse N2a neuroblastoma cultures (ScN2a) were plated at 2–
46106 in Opti-MEM medium [0.5% (W/V) glucose supplement-
ed with 5% fetal bovine serum (FBS), 50 U/ml penicillin, 50 mg/
ml streptomycin and 200 mM L-glutamine]. Cultures were
maintained at 37C in 5% CO2 with a change of medium every
48–72 hours.
10. Immunofluorescence staining and imaging of PrPSc
oligomers
For subsequent staining with PRIOC antibodies, N2a, ScN2a or
prn-p0/0 glial cells were first seeded on glass coverslips in 35-mm
dishes and grown to 50% confluence at 37uC in a humidified
atmosphere of 5% CO2/95% on air. Cells were fixed in 300–
500 ml cold (4uC) 3.5–4% (w/v) paraformaldehyde (Fisher
Scientific) in TBS for 20 mins at RT prior to staining with
antibody for 1 hour. Other cells were subjected to Triton X-100
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treatment in order permeabize the cell membrane. After washing
the coverslips with TBS, 100 ml of blocking buffer [(1% (v/v) FBS,
1% BSA (w/v) in TBS] was added. The coverslips were incubated
with 100 ml of 5 mg PRIOC or 1 mg positive anti-PrP antibody
control (Sigma) for 1 hour at RT followed by the secondary
antibodies diluted in TBS [(anti-mouse IgM FITC-conjugate,
Sigma; anti-goat IgG Texas red-conjugate, Sigma)] for 1 hour at
RT. After the final wash in TBS, the coverslips were mounted in
fluorescence anti-fade solution (Invitrogen) and sealed with clear
nail polish to prevent dehydration.
Florescence microscopy was performed with a Leica DM4000B
microscope. Images from each source [FITC (450–490 nm), and
Texas red (510–560 nm)] were collected by a high resolution
DC500 colour camera attached. All images are saved digitally
using Leica’s IM500 Image Manager Database software from the
same field-of-view. Images were merged using Photoshop 6.0
(Adobe). Confocal laser scanning microscopy was performed with
a Zeiss LSM510 confocal system on an inverted Zeiss Axio100M.
Z-series and snapshot images were collected. Dual scans were
merged using Photoshop 6.0 (Adobe).
11. Flow cytometry
ScN2a cells were grown to confluence. Appropriate concentra-
tions of these cells (,107) were aliquoted into FACS tubes (BD)
and washed twice with Hank’s medium (Sigma) at 1200 rpm for
5 minutes at 4uC. The tubes were transferred onto ice and PRIOC
antibody were added and left to incubate for at least one hour.
The cells were washed 3 times in Hank’s medium and secondary
anti-IgM or negative control anti-IgG FITC-conjugate (Sigma)
was added subsequently and left to incubate for another hour.
Finally, the cells were washed three times in Hank’s medium and
scanning was performed.
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